The year in charts

Tuesday, April 25, 2023 @ 7:00 am

Capital investments in Swiss biotech companies 2012-2022

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Total Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2020-2022 — Note: The 2022 data in above tables is based on information that was available up until March 31, 2023. At this time, some of the companies had not yet disclosed
their financial figures for 2022. Therefore some figures were carefully extrapolated on the basis of the latest interim data publicly available (i.e. Q3 or Q4 2022).

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Public Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Private Swiss Biotech Companies

Number of biotech companies in Switzerland 2013-2022

Number of employees in Swiss R&D biotech companies 2020-2022

Tags

You may also be interested in

Swiss Biotech Report 2023 shows sector weathers global disruption well and continues to play a leading role driving global healthcare innovation

April 25, 2023

GeNeuro: One of the largest trials against long-COVID

November 28, 2023

InSphero and ATCC: 3D cell-based assays for oncology research

November 17, 2023

Versameb: FDA clearance for stress urinary incontinence investigational new drug

November 16, 2023

ACROBiosystems launches the world’s first GMP-grade DLL-4 Protein

November 16, 2023

Nouscom raises EUR 67.5 million in series C financing round

November 14, 2023